Insider Selling: Moderna, Inc. (NASDAQ:MRNA) Insider Sells 5,178 Shares of Stock

Moderna, Inc. (NASDAQ:MRNAGet Free Report) insider Shannon Thyme Klinger sold 5,178 shares of the stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $148.09, for a total value of $766,810.02. Following the transaction, the insider now owns 15,947 shares in the company, valued at approximately $2,361,591.23. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Shannon Thyme Klinger also recently made the following trade(s):

  • On Tuesday, May 28th, Shannon Thyme Klinger sold 1,296 shares of Moderna stock. The stock was sold at an average price of $162.47, for a total value of $210,561.12.

Moderna Trading Down 1.7 %

NASDAQ MRNA opened at $145.23 on Friday. The company has a quick ratio of 3.91, a current ratio of 4.03 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a twelve month low of $62.55 and a twelve month high of $170.47. The company has a market cap of $55.66 billion, a price-to-earnings ratio of -9.27 and a beta of 1.54. The business’s fifty day moving average is $128.21 and its 200 day moving average is $107.72.

Moderna (NASDAQ:MRNAGet Free Report) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, beating the consensus estimate of ($3.59) by $0.52. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The company had revenue of $167.00 million for the quarter, compared to the consensus estimate of $93.26 million. During the same quarter last year, the business posted $0.19 EPS. Moderna’s revenue for the quarter was down 91.0% on a year-over-year basis. As a group, sell-side analysts expect that Moderna, Inc. will post -7.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on MRNA shares. HSBC reiterated a “reduce” rating and set a $86.00 target price (up previously from $75.00) on shares of Moderna in a research note on Monday, February 26th. UBS Group raised their price objective on Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a research note on Tuesday, May 7th. William Blair restated a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Oppenheimer raised their price objective on Moderna from $163.00 to $179.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Jefferies Financial Group restated a “buy” rating and set a $125.00 price objective on shares of Moderna in a research note on Tuesday, April 9th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Moderna has a consensus rating of “Hold” and an average target price of $129.02.

View Our Latest Stock Analysis on MRNA

Institutional Investors Weigh In On Moderna

Hedge funds have recently modified their holdings of the company. Ogorek Anthony Joseph NY ADV acquired a new stake in shares of Moderna during the 4th quarter valued at $27,000. Arlington Trust Co LLC raised its position in Moderna by 4,833.3% during the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after purchasing an additional 290 shares during the last quarter. Cedar Wealth Management LLC raised its position in Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after purchasing an additional 90 shares during the last quarter. Westside Investment Management Inc. bought a new position in Moderna during the 1st quarter worth $32,000. Finally, Rise Advisors LLC raised its position in Moderna by 953.3% during the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after purchasing an additional 286 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

About Moderna

(Get Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Featured Stories

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.